The stock is listed on the Nasdaq Global Market

Davis Polk advised the co-lead book-running managers and representatives of the several underwriters in connection with a $57.5 million SEC-registered follow-on offering by Coherus BioSciences, Inc. of 13,529,411 shares of common stock (which includes the exercise in full by the underwriters of their option to purchase up to 1,764,705 additional shares). The common stock is listed on the Nasdaq Global Market under the symbol “CHRS.”

Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative cancer treatments and the commercialization of their portfolio of FDA-approved biosimilars.

The Davis Polk corporate team included partner Alan F. Denenberg and associates Paula Gergen and Karen Yang. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post